Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that t(KMT2A;v) status confers therapeutic sensitivity to Revumenib in patients with Burkitt Lymphoma.
The U.S. Food and Drug Administration (FDA) granted approval to revumenib for the treatment of adult and pediatric patients 1 year and older with relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation.
This statement is based on a regulatory approval from the Food and Drug Administration:
REVUFORJ is a menin inhibitor indicated for the treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients 1 year and older.